Kazia Therapeutics
KZIA
8 hedge funds and large institutions have $328K invested in Kazia Therapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
551% more capital inflows, than outflows
Capital inflows: $20.1K | Capital outflows: $3.09K
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
14% more funds holding
Funds holding: 7 → 8 (+1)
0.06% more ownership
Funds ownership: 1.33% → 1.39% (+0.06%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$9.5K |
| 2 |
Morgan Stanley
New York
|
+$6.43K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$4.16K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Belpointe Asset Management
Reno,
Nevada
|
-$3.09K |
KZIA Hedge Fund Activity: Q2 2023 in Review
8 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q2 2023, worth a combined $328K — up 17% from $279K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new KZIA positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was RhumbLine Advisers, opening a new position worth an estimated $9.5K. The largest seller was Belpointe Asset Management, exiting entirely with an estimated $3.09K sold.
- 8 institutional investors held Kazia Therapeutics (KZIA) as of Q2 2023, up from 7 in Q1 2023.
- Funds reported $328K of Kazia Therapeutics stock for Q2 2023, up 17% quarter-over-quarter.
- 2 funds opened new Kazia Therapeutics positions in Q2 2023 and 1 closed out, a net change of +1 holder.
- The largest Kazia Therapeutics buyer in Q2 2023 was RhumbLine Advisers, an estimated $9.5K added.
- The largest Kazia Therapeutics seller in Q2 2023 was Belpointe Asset Management, an estimated $3.09K sold.
Based on aggregated 13F filings for Q2 2023.